SCHEMBL6152782

SCHEMBL6152782

[NH]Cc1cc(C(F)(F)F)ccc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.43
SLC6A4 P31645 4/20 0.43
SLC6A2 P23975 1/20 0.43
HTR2A P28223 3/20 0.42
KCNH2 Q12809 3/20 0.42
PDE2A O00408 2/20 0.41
ALDH1A1 P00352 2/20 0.40
TRAP1 Q12931 3/20 0.39
HSP90AA1 P07900 1/20 0.39
HSP90B1 P14625 1/20 0.39
MEN1 O00255 1/20 0.38
TSHR P16473 1/20 0.38
KMT2A Q03164 1/20 0.38
ATM Q13315 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CHRNA7 P36544 1/20 0.38
DAO P14920 1/20 0.38
PIEZO1 Q92508 1/20 0.38
MCL1 Q07820 1/20 0.37
CYP3A4 P08684 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10656350 0.83 SLC6A4 (0.48) IDO1SLC6A4SLC6A2HTR2AKCNH2
SCHEMBL5436712 0.82 SLC6A4 (0.43) IDO1SLC6A4SLC6A2HTR2AKCNH2
SCHEMBL146337 0.80 SLC6A4 (0.43) IDO1SLC6A4SLC6A2HTR2AKCNH2
SCHEMBL10050765 0.80 SLC6A4 (0.46) SLC6A4SLC6A2HTR2AKCNH2PDE2A
SCHEMBL856434 0.80 PNMT (0.43) IDO1SLC6A4SLC6A2HTR2AKCNH2
SCHEMBL29594772 0.80 SLC6A4 (0.46) IDO1SLC6A4SLC6A2HTR2AKCNH2
SCHEMBL5235367 0.80 ALDH1A1 (0.43) IDO1SLC6A4SLC6A2HTR2AKCNH2
SCHEMBL5500903 0.80 ALDH1A1 (0.43) IDO1SLC6A4SLC6A2HTR2AKCNH2
SCHEMBL5500906 0.80 IDO1 (0.43) IDO1SLC6A4SLC6A2HTR2AKCNH2
SCHEMBL271188 0.80 SLC6A4 (0.46) IDO1SLC6A4SLC6A2HTR2AKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050080261-A1 Purine inhibitors of cyclin dependent kinase 2 and IkappaB-alpha LUM ROBERT T (US) 2005-04-14 US claimed
EP-1150982-B1 PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkB-alpha CV THERAPEUTICS INC (US) 2005-10-12 EP disclosed
US-6790958-B2 ANTIPROLIFERATIVE AGENTS; FUNGICIDES LUM ROBERT T (US) 2004-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080261-A1 Purine inhibitors of cyclin dependent kinase 2 and IkappaB-alpha IKBKB, NFKB1, CDK4 IDO1 2053/4885SLC6A4 2527/4885SLC6A2 2872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.